/
Analysis at the Speed of Life We are making chemical analysis simple, smart and speedy with our purpose-built handheld devices that empower people to take swift action in life-altering applications. Company Overview We have developed an innovative suite of purpose-built handheld devices for point-of-need chemical analysis.
$7.15
$0.20 (-2.72%)
Live · 05:19 PM
The business is unprofitable at the operating level (-70.15% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 17.7% YoY with margins expanding 50.1pp.
Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$58M
▲ +17.7% YoY
Net Income (TTM)
-$36M
▲ +127.0% YoY
Op. Margin
-71.42%
▲ +50.1pp YoY
ROIC
-22.46%
▲ +7.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▲ +20.1% YoY
Op. Cash Flow (TTM)
-$7M
▲ +21.7% YoY
Net Debt
-$107M
Net Cash Position
Cash & Equiv.
$112M
5Y CAGR: +15.9%
Continue Research
908 Devices (MASS)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, 908 Devices scores 36/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
908 Devices scores 36 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -71.4% operating margin and a -22.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MASS's valuation and scores 36/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.